Drug Profile
Thrombomodulin alfa - Asahi Kasei Pharma Corp
Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma Corp; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alfa - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alpha - Asahi Kasei Pharma Corp; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma Corp; Thrombomodulin alpha - Asahi Kasei Pharma Corp; TMD-123Latest Information Update: 25 Feb 2022
Price :
$50
*
At a glance
- Originator Asahi Kasei; Asahi Kasei Pharma Corp
- Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
- Class Anti-inflammatories; Anticoagulants; Antifibrotics; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
- Mechanism of Action Protein C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Disseminated intravascular coagulation
- Phase II Peripheral nervous system diseases
- Discontinued Deep vein thrombosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 24 Feb 2022 Veloxis Pharmaceuticals plans a phase I trial for Colorectal cancer (Combination therapy, Metastatic disease) and Peripheral neuropathies (Chemotherapy-induced) in February 2022 (IV) (NCT05251727)
- 02 Feb 2022 Veloxis Pharmaceuticals withdrew a phase II trial prior to enrolment due to change in study design in Peripheral nervous system diseases (Prevention) (IV) (NCT04492436)
- 16 Mar 2021 Phase III development is ongoing in Disseminated intravascular coagulation in sepsis (severe sepsis with coagulopathy) outside Japan (IV) (Asahi Kasei Pharma Corp website, March 2021)